Intercept's Ocaliva approval in jeopardy after FDA flags concerns in advisory committee briefing doc
Fierce Pharma
SEPTEMBER 11, 2024
. | Ahead of an advisory committee meeting slated for Friday, the FDA unleashed damning briefing documents calling into question the effectiveness and safety of Intercept’s rare liver disease drug Ocaliva.
Let's personalize your content